Pfizer Agrees To Settle Over 10,000 Lawsuits Linking Heartburn Drug To Cancer

Fact checked by The People's Voice Community
Pfizer Zantac

Pfizer has agreed to settle more than 10,000 lawsuits accusing the big pharma giant of hiding the cancer risks of their anti-heartburn medication Zantac.

The lawsuits were filed in courts across the US, but the agreements don’t completely resolve Pfizer’s exposure to the claims that linked the drug to cancer.

The Pfizer agreements cover cases in US state courts but don’t completely resolve the company’s exposure to Zantac claims, people familiar with the matter told Bloomberg News.

Financial details of the deals were not immediately available. 

The Mail Online reports: The financial details have not been revealed but pharma rival Sanofi agreed to pay more than $100million to resolve 4,000 Zantac-cancer claims last nonth.

The over-the-counter pill was pulled in the US in 2020 after animal studies found a key ingredient released ‘probable human carcinogens’.

Pfizer was the primary manufacturer of Zantac from 1998 to 2006, when several suits claim it should have known that the drug was contaminated with NDMA.

Plaintiffs claimed the drug was contaminated with the impurity through improper manufacturing practices, and that Pfizer withheld this information from consumers.

NDMA is a chemical byproduct of many industrial manufacturing processes, including the production of rocket fuel.

It’s also common in low quantities in many foods, such as cured or smoked meats, fish and beer as well as tobacco smoke. 

NDMA is a ‘forever chemical,’ meaning that it doesn’t degrade, or break down, naturally in our bodies and is believed to cause DNA damage.

Since the drug was pulled and reformulated, thousands of lawsuits began piling up in federal and state courts against Pfizer, GSK, Sanofi and Boehringer Ingelheim, who have all owned the rights to the medication.

Niamh Harris
About Niamh Harris 15017 Articles
I am an alternative health practitioner interested in helping others reach their maximum potential.